MRPL13 and malignant epithelial tumor of ovary: The results indicated that both the positive expression rate and high positive expression rate of MRPL13 were significantly higher in ovarian epithelial malignant tumors (93.86% and 73.68%, respectively) compared to borderline ovarian tumors (69.70% and 39.39%, respectively), benign ovarian tumors (41.94% and 19.35%, respectively), and normal ovarian tissues (30.77% and 15.38%, respectively).